Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Acq. announced
Quarterly results
Director departure
Appointed director

WaferGen Bio-systems, Inc. (WGBS) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/01/2017 8-K Quarterly results
02/15/2017 8-K Form 8-K - Current report
11/28/2016 8-K Form 8-K - Current report
11/15/2016 8-K Form 8-K - Current report
11/08/2016 8-K Quarterly results
Docs: "WaferGen Bio-systems Reports Results for Third Quarter 2016 Year-to-Date Revenues Represent 44% Growth over First Nine Months of 2015 FREMONT, California – November 8, 2016 – WaferGen Bio-systems, Inc. , a life sciences company focused on developing and commercializing technology platforms for genomic solutions, announced today its financial results for the third quarter ended September 30, 2016. Key Recent Highlights"
10/31/2016 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Investor Contact:"
10/28/2016 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Letter to stockholders, sent by WaferGen Bio-systems, Inc., furnished herewith"
10/27/2016 8-K Form 8-K - Current report
08/09/2016 8-K Quarterly results
Docs: "WaferGen Bio-systems Reports Results for Second Quarter 2016 Second Quarter Revenues Represent 56% Growth over Second Quarter of 2015 and 30% Growth over First Quarter of 2016 FREMONT, California – August 9, 2016 – WaferGen Bio-systems, Inc. , a life sciences company focused on developing and commercializing technology platforms for genomic solutions, announced today its financial results for the second quarter ended June 30, 2016. Key Recent Highlights"
05/26/2016 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/13/2016 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "Agreement and Plan of Merger, among Takara Bio USA Holdings, Inc., Walrus Acquisition Corporation, WaferGen Bio-systems, Inc. and Takara Bio USA, Inc",
"Deposit Agreement, between Takara Bio USA Holdings, Inc. and WaferGen Bio-systems, Inc",
"Second Amendment to Executive Employment Agreement, effective as of May 12, 2016, between WaferGen Bio-systems, Inc. and Ivan Trifunovich",
"WaferGen Bio-systems and Takara Bio Inc. Announce Merger Agreement Transaction scheduled to close following completion of the 2016 fiscal year"
05/10/2016 8-K Form 8-K - Current report
03/09/2016 8-K Form 8-K - Current report
03/08/2016 8-K Form 8-K - Current report
02/16/2016 8-K Termination of a Material Definitive Agreement
01/28/2016 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "WaferGen Bio-systems Announces 50 Percent Year-Over-Year Growth in Fourth Quarter 2015 Revenues Fourth Quarter Revenues Include Initial Two ICELL8™ Single-Cell System Sales and Represents 15-25% Growth Over Third Quarter 2015 Revenues Company Provides Full-Year 2016 Revenue Guidance; Expecting 70 Percent Growth Over Full-Year 2015 Revenues FREMONT, California, January 28, 2016 -- WaferGen Bio-systems today announced preliminary, unaudited revenue for the fourth quarter of 2015. The Company expects total revenue for the fourth quarter of 2015 to be in the range of $2.3 million to $2.5 million, which would represent an increase of 43-55% when compared to the $1.6 million reported for the fourth quarter of 2014. This also represents a sequential increase of 14-24% compared to the $2.0 m..."
12/28/2015 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
11/10/2015 8-K Quarterly results
Docs: "15Q3ER"
10/21/2015 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "Certificate of Designation of the Series 2 Convertible Preferred Stock",
"Certificate of Designation of the Series 2 Convertible Preferred Stock"
08/05/2015 8-K Quarterly results
Docs: "WaferGen Bio-systems Reports Results for Second Quarter 2015 Company Continues to Advance Single Cell Analysis Technology According to Plan; Full Commercial Launch on Track for Fourth Quarter of 2015 Early Access Program for WaferGen’s Single Cell Analysis Technology Fully Enrolled; Initial Data Anticipated in Third Quarter FREMONT, California -- August 5, 2015 – WaferGen Bio-systems, Inc. announced today its financial results for the second quarter and six months ended June 30, 2015. Key Recent Highlights"
07/07/2015 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/10/2015 8-K Submission of Matters to a Vote of Security Holders
05/11/2015 8-K Appointed a new director
Docs: "Carlson Employment Agreement, effective as of May 11, 2015, between the Company and Rolland Carlson",
"Amendment to Executive Employment Agreement, effective as of May 11, 2015, between the Company and Ivan Trifunovich",
"WaferGen Bio-systems Appoints Life Sciences Industry Veteran, Rolland D. Carlson, Ph.D., President & CEO Ivan Trifunovich, Ph.D., Appointed Executive Chairman of the Board New CEO to Lead WaferGen’s Commercial Efforts in Single Cell Analysis"
05/11/2015 8-K Quarterly results
Docs: "WaferGen Bio-systems Reports Results for First Quarter 2015 Company Continues to Advance Single Cell Analysis Technology, Full Commercial Launch Expected by End of 2015 Early Access Program for WaferGen’s Single Cell Analysis Technology Initiated; Company Collaborating with Genentech, National Jewish Hospital and Karolinska Institutet Company Reiterates 2015 Revenue Guidance"
03/16/2015 8-K Quarterly results
Docs: "WaferGen Bio-systems Reports Results for Fourth Quarter and Fiscal Year 2014 Record Growth in 2014 Revenues, up 360 Percent over 2013 Significant Progress Achieved with Single Cell Analysis Technology, Full Commercial Launch Expected by End of 2015 Company Provides 2015 Revenue Guidance of $8.0 - $8.5 Million, Which Would Represent an Increase of 33% - 42% FREMONT, California -- March 16, 2015 /PRNewswire/ – WaferGen Bio-systems, Inc. announced today its financial results for the fourth quarter and year ended December 31, 2014. Key 2014 and Recent Highlights"
11/18/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amended and Restated Bylaws of WaferGen Bio-systems, Inc"
11/07/2014 8-K Quarterly results
Docs: "WaferGen Bio-systems Announces Third Quarter 2014 Results Solid Execution Across SmartChip and Apollo Product Lines Appointment of Chief Operating Officer and Chief Financial Officer Completion of $20 million offering of Common Stock and Warrants"
08/18/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Executive Employment Agreement, effective as of August 25, 2014, between the Company and Michael Henighan",
"Executive Employment Agreement, between the Company and Keith Warner",
"Press Release"
08/11/2014 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Transcript for conference call held August 7, 2014, furnished herewith"
08/07/2014 8-K Quarterly results
Docs: "WaferGen Bio-systems Reports Strong Revenue Growth for Q2 2014 Solid Execution Across SmartChip and Apollo Product Lines FREMONT, Calif., August 7, 2014 /PRNewswire/ -- WaferGen Bio-systems, Inc. announced today its financial results for the second quarter ended June 30, 2014. Key Highlights"
07/18/2014 8-K Resignation/termination of a director
Docs: "WaferGen Bio-Systems Announces Appointment of Ivan Trifunovich as Chairman of the Board; Joel Kanter to Serve as Lead Independent Director FREMONT, Calif., July 18, 2014 /PRNewswire/ -- WaferGen Bio-systems, Inc. today announced that its Board of Directors has appointed Ivan Trifunovich, the company’s President and Chief Executive Officer, as Chairman of the Board. Joel Kanter, a director of the company since 2007, will serve as lead independent director. Alnoor Shivji, the company’s Chairman since 2002, resigned from the board to focus full time on a new startup venture. “I would like to thank Alnoor for his service to WaferGen while it grew from a start-up to a public company with commercially viable products. Speaking for the whole Board, I wish him success in his future endeavors”, com..."
06/30/2014 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
Docs: "Certificate of Amendment to the Amended and Restated Articles of Incorporation of the Company",
"WaferGen Bio-systems Announces Reverse Stock Split as it Pursues NASDAQ Listing FREMONT, Calif., June 30, 2014 /PRNewswire/ -- WaferGen Bio-systems, Inc. announced today a 1-for-10 reverse stock split of its outstanding common stock. The company completed the reverse stock split as it seeks to list its common stock on the NASDAQ Capital Market. The reverse stock split became effective at 1:01 p.m. Pacific Time on June 30, 2014. WaferGen’s common stock will begin trading on a split adjusted basis on the OTCBB when the market opens on July 1, 2014. The common stock will have a new CUSIP number, 93041P 308, and will trade for 20 days under the temporary trading symbol, “WGBSD,” with the “D” added to signify that the reverse stock split has occurred. As a result of the reverse stock split, eve..."
05/30/2014 8-K Appointed a new director
05/13/2014 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Transcript for conference call held May 8, 2014, furnished herewith"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy